Scalper1 News
Biotech stocks continued to slide Thursday, prompting analysts to weigh in on the causes and prognosis for the sector. Piper Jaffray’s Joshua Schimmer noted that the same thing happened about a year ago, sparked by the price debate over Gilead Sciences’ (GILD) hepatitis C drug Sovaldi, but also by valuation concerns after a long runup. “Obviously 2014 turned out to be a stellar year for biotech, and we believe industry fundamentals remain strong,” Scalper1 News
Scalper1 News